Archive Page: High throughput gene editing | Cellular Operations

Archive Page: High throughput gene editing | Cellular Operations

High throughput gene editing

The High-Throughput and Gene Editing team was disbanded in 2019 with the formation of the new Gene Editing team at the Sanger Institute. This page is being maintained as a historical record of the team's work at the Institute and is no longer being updated.
High Throughput Gene Editing Team
High Throughput Gene Editing Team

Our Research and Approach

The High Throughput Gene Editing team helped to deliver the gene editing requirements of the Institute's faculty and research.

We did this by:

  • Supporting the gene editing needs of the Institutes varied research programmes, through the adoption of modern genome editing techniques.
  • We aimed to optimise and develop genome editing tools and platforms to provide an agile, project focused, cost effective and efficient service for our collaborating partners.
  • We provided training, resources and technical support for research groups and their staff.

People

Dovey, Oliver
Dr Oliver M Dovey
Group Leader

Oliver leads the Gene Editing, Cellular Operations group. Having started his career as a research assistant at the Sanger Institute, with the Microarray Facility (lead by Cordelia Langford) and the Mouse Genetics team (lead by Prof. Allan Bradley), he obtained his PhD from the University of Leicester with Prof. Shaun Cowley studying the molecular and physiological effects of chromatin modifying proteins through the use of engineered Stem Cells and murine models. From here he returned to the Sanger Institute to study Haematological Cancer Genetics with Prof. George Vassiliou. Using bespoke engineered murine models, reverse (CRISPR-ko) and forward (transposon mediated insertional mutagenesis) screening platforms he worked to determine the physiological, molecular, pharmacological and genetic interactions (as well as sensitivities) of Acute Myeloid Leukaemia. He took up post as Head of Cellular Operations Gene Editing Team (formerly High Throughput Gene Editing) in 2018 and his team perform experiments which require Genome Engineering and develop an array of Gene Editing tools and platforms for the Institute.

Show Alumni

Alumni

Key Projects, Collaborations, Tools & Data

Cancer Dependency Map

The Cancer Dependency Map integrates the work of multiple experimental and computational research project at the Sanger Institute with the shared aim of identifying dependencies in cancer cells which could be exploited to develop new therapies. This knowledge is foundational for our understanding of cancer biology and the development of precision cancer medicine.

Deciphering Developmental Disorders (DDD)
The aim of the Deciphering Developmental Disorders (DDD) Study is to advance clinical genetic practice for children with developmental disorders by the systematic application of the latest microarray and sequencing methods while addressing the new ethical challenges raised.
HipSci

Hundreds of induced pluripotent stem cell lines for cellular genetic analysis

PlasmoGEM - TOOLS

PlasmoGEM is a non-profit, open-access malaria research resource, providing tools for the manipulation of Plasmodium genomes, and using them to carry out large-scale research projects.

WGE - CRISPR design tool

WTSI Genome Editing (WGE) is a website and database that provides tools for designing genome editing of human and mouse genomes using CRISPR/Cas9

Partners and Funders

Internal Partners
Adams Group
We are a team of cancer biologists, geneticists and computational biologists interested in understanding how cancers develop and the ways of controlling their growth. We work on a range of malignancies but are particularly interested in melanoma and other skin cancers.
Cellular Generation and Phenotyping
The Cellular Generation and Phenotyping (CGaP) core facility provides central cell biology support to the Sanger Institute. CGaP takes a unique approach at the institute by partnering with faculty groups in order to deliver the scale-up of existing protocols to facilitate 'Science at Scale'. We function as a contract research group for the institute, running multiple, distinct cell biology based projects. The facility has expertise in cell derivation from primary tissue, iPSC and organoid derivation, cellular differentiation, CRISPR library screening, functional bioassays, phenotypic assays and end point analysis (e.g. Immunocytochemistry).
Garnett Group
The Translational Cancer Genomics team investigate how genetic alterations in cancer contribute to disease and impact on response to therapy.
Hurles Group
The Hurles group studies the genetic causes and mechanisms of rare genetic disorders and how DNA mutates as it is pass on from one generation to the next.
Parts Group
Our goal is to understand how genetic background influences outcome of mutations. To do so, we measure, model, and modulate cell state across healthy and disease-relevant human genetic diversity. In the lab, we develop tools for genetic perturbations, and use genome engineering and synthetic biology to create cell lines for screening cellular traits. In the office, we develop probabilistic models as well as software tools to accurately and efficiently analyse the readouts.
Stem Cell Informatics

Stem Cell Informatics (SCI) develops custom laboratory information systems (LIMS) and computational research tools (WGE) for high-throughput laboratory analysis of human stem cells.

Thomson Group
The bacterial genomics and evolution team focuses primarily on using whole-genome sequencing approaches to study the patterns and drivers for historical and ongoing pathogen genome evolution. This is then combined with screens in whole cells or model organisms to understand the phenotypic consequences of those changes.
Vassiliou Group

The Haematological Cancer Genetics team, led by George Vassiliou, studies the genes and genetic pathways involved in the development of blood cancers, with a particular emphasis on Acute Myeloid Leukaemia and related malignancies. The ultimate goal of the team is to develop methods for early detection of those at risk of blood cancers and new treatments that can improve the survival and quality of life of blood cancer sufferers.

Vidal-Puig Group

We aim to learn why being obese causes metabolic and cardiovascular problems and to provide the rational for mechanistically driven therapeutic approaches to prevent these complications which are the meain cause of morbidity among obese patients.

Publications

  • Exploiting induced pluripotent stem cell-derived macrophages to unravel host factors influencing Chlamydia trachomatis pathogenesis.

    Yeung ATY, Hale C, Lee AH, Gill EE, Bushell W et al.

    Nature communications 2017;8;15013

    PUBMED: 28440293; PMC: 5414054; DOI: 10.1038/ncomms15013

  • One-step generation of conditional and reversible gene knockouts.

    Andersson-Rolf A, Mustata RC, Merenda A, Kim J, Perera S et al.

    Nature methods 2017;14;3;287-289

    PUBMED: 28135257; PMC: 5777571; DOI: 10.1038/nmeth.4156

Twitter